Navigation Links
FDA Clears Software Upgrade for Fenwal Plasma-Collection System
Date:8/19/2010

LAKE ZURICH, Ill., Aug. 19 /PRNewswire/ -- Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market a new software release for its Autopheresis-C® system.  Blood and plasma centers worldwide use the Autopheresis-C system to collect plasma from donors.

The new software includes many new features designed to improve plasma collection for plasma- and blood-center professionals and donors.  The software helps automate and streamline collection processes, which reduce the need for operator intervention and help to improve work flow and reduce procedure times.  New confirmatory prompts are designed to make accurate programming for target plasma volumes even easier.

"The Autopheresis-C® system has long been an industry standard for collecting plasma of exceptional quality," said William H. Cork, chief technology officer for Fenwal.  "Our customers can now expect a series of innovations from Fenwal designed to make great instruments even better in terms of speed, ease of use and communications with plasma center information systems."

Plasma is the liquid portion of blood that contains valuable proteins used to treat burn victims, bleeding disorders, and for several therapeutic applications under development, such as for Alzheimer's disease, heart disease, and some cancers.  Plasma-derived proteins have become integral to many novel medical therapies in late-stage development.  Fenwal has established technical partnerships with pharmaceutical companies to assist them in this research and development.

About Fenwal

Fenwal, Inc. is a global medical technology company focused on improving blood collection, filtration, separation, storage and transfusion to ensure the availability, safety and effectiveness of blood components.  Fenwal is unique in the depth of its experience and commitment to transfusion medicine.  The company offers the broadest range of products for the automated and manual collection of blood and blood components.  Fenwal became an independent company in 2007, but its roots go back to 1949 with the founding of Fenwal Laboratories.  Fenwal developed the first flexible, single-use container for blood collection, eliminating complications associated with glass containers and allowing blood to be separated into therapeutic components.  Today, the company's products and advanced collection and separation technologies are used to help treat patients on six continents.  Fenwal, Inc. is based in Lake Zurich, Illinois.  For more information, please visit www.fenwalinc.com.


'/>"/>
SOURCE Fenwal, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Clears AirStrip RPM for CRITICAL CARE & CARDIOLOGY Remote Patient Monitoring Solutions
2. FDA Clears Xlumenas NAVIX(TM) Access Device
3. FDA Clears Three Additional Antimicrobials for Use on TREK Sensititre(R) In Vitro Diagnostic (IVD) MIC Susceptibility Plates: Minocycline and Telavancin Used to Treat MRSA and Other Infections; and Tigecycline, Now Cleared for Streptococcus Pneumoni
4. FDA Clears the Fenwal Amicus(R) Separator System for Collecting Platelets in New Additive Solution
5. FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology
6. FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets
7. U.S. Food and Drug Administration Clears Alcatel-Lucent Remote Patient Monitoring Solution for Sale in the United States
8. Private Investment Firm Czura Thornton Today Introduces Clearstone Central Laboratories as the Newest Member of the Czura Thornton Life Science Group
9. FDA Clears a Test for Ovarian Cancer
10. U.S. Food and Drug Administration Clears Way for Multi-Center Clinical Trial of IDEV Technologies SUPERA Peripheral Stent
11. FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... 2016 , ... First Choice Emergency Room , the largest network of ... Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased to ... said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
Breaking Medicine News(10 mins):